Robert Lechleider Buys 15,805 Shares of Immunome, Inc. (NASDAQ:IMNM) Stock

Immunome, Inc. (NASDAQ:IMNM) insider Robert Lechleider acquired 15,805 shares of the company’s stock in a transaction on Thursday, November 21st. The shares were acquired at an average cost of $9.48 per share, for a total transaction of $149,831.40. Following the completion of the acquisition, the insider now owns 15,805 shares of the company’s stock, valued at approximately $149,831.40. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Immunome Price Performance

NASDAQ:IMNM traded up $1.16 during trading hours on Monday, hitting $10.98. The stock had a trading volume of 351,854 shares, compared to its average volume of 771,478. The company has a 50 day simple moving average of $12.58 and a two-hundred day simple moving average of $13.58. The firm has a market capitalization of $685.37 million, a price-to-earnings ratio of -1.35 and a beta of 1.82. Immunome, Inc. has a one year low of $6.93 and a one year high of $30.96.

Analysts Set New Price Targets

IMNM has been the topic of a number of recent research reports. Piper Sandler dropped their price target on shares of Immunome from $23.00 to $21.00 and set an “overweight” rating on the stock in a research note on Thursday, November 14th. Stephens assumed coverage on Immunome in a research report on Friday, November 8th. They set an “overweight” rating and a $30.00 target price on the stock. Finally, Wedbush reiterated an “outperform” rating and issued a $33.00 price target on shares of Immunome in a research report on Friday, October 25th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $28.83.

Institutional Investors Weigh In On Immunome

Institutional investors and hedge funds have recently made changes to their positions in the business. Sofinnova Investments Inc. increased its holdings in shares of Immunome by 10.3% in the 2nd quarter. Sofinnova Investments Inc. now owns 655,680 shares of the company’s stock worth $7,934,000 after buying an additional 61,284 shares during the last quarter. Cetera Investment Advisers bought a new stake in Immunome during the first quarter worth about $3,038,000. Victory Capital Management Inc. increased its position in shares of Immunome by 48.1% during the 3rd quarter. Victory Capital Management Inc. now owns 730,785 shares of the company’s stock valued at $10,684,000 after purchasing an additional 237,497 shares during the last quarter. Price T Rowe Associates Inc. MD raised its holdings in shares of Immunome by 113.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,245,673 shares of the company’s stock valued at $55,425,000 after buying an additional 1,194,451 shares in the last quarter. Finally, Ensign Peak Advisors Inc bought a new position in Immunome during the second quarter valued at approximately $1,379,000. Hedge funds and other institutional investors own 44.58% of the company’s stock.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.